DoW Breast Cancer, Clinical Research Extension Award

Key facts

Copied from the official Grants.gov record. Last verified October 29, 2026.

Program name

DoW Breast Cancer, Clinical Research Extension Award

Issuing agency

Defense Health Agency Contracting Activity - DHACA (Department of Defense)

Opportunity number

HT942526BCRPCREA2

Funding type

Grant

Funding purpose

Science and Technology and other Research and Development

Status

Open (posted)

Application deadline

Closes November 18, 2026(19 days left)

Published award range

Not published by the agency

Estimated total program funding

$8,400,000

Expected number of awards

1

Cost sharing or match required

No

Eligible applicants (official categories)

• Unrestricted (open to any type of entity, subject to any clarification in Additional Information on Eligibility)

Relevant to

Businesses and NonprofitsHow we determined this: Grants.gov lists eligibility as Unrestricted.

Geographic restrictions

None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.

Assistance Listing (CFDA)

12.420

Official source

View on Grants.gov ↗

Application URL

www.grants.gov/search-results-detail/363671 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.

Source identifier

Grants.gov opportunity ID 363671 · Funding opportunity number HT942526BCRPCREA2

Posted

September 3, 2026 · Source last updated September 3, 2026

Last verified

October 29, 2026 (against Grants.gov)

Data completeness

83% of key fields published by the sourceNot published: published funding range, eligibility criteria text.

Record confidence

highVerified against the official source; key fields present; no open issues.

Description (from the official listing)

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.Distinctive Features:• The research team must include two or more breast cancer consumer advocates.• This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Agency contact

eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
help@eBRAP.org